CPT Codes

81120 - IDH1 Mutation Detection
81121 - IDH2 Mutation Detection

Synonyms

  • IDH1 [isocitrate dehydrogenase (NADP(+)) 1]
  • IDH2 [isocitrate dehydrogenase (NADP(+)) 2]
  • AML

Test Includes

IDH1 Mutation Detection – Identification of codon 132 mutations in IDH1 gene
IDH2 Mutation Detection – Identification of codon 140 and 172 mutations in IDH2 gene

Performing Laboratory / Facility

UCLA Molecular Diagnostics Laboratories (MDL)

Performing Section

Molecular Pathology

Availability

Monday through Friday, 0700-1700

Turnaround Time

2-5 business days from receipt of specimen in performing lab

Methodology

IDH1 and IDH2 Idylla Assay is a real- time PCR assay using a cartridge -based design for the detection of somatic mutations in IDH1 and IDH2 genes. The test detects mutations of R132C/H/G/S/L in codon 132 of the IDH1 gene. The test also detects mutations R140Q/L/G/W and R172K/M/G/S/W in codon 172 of the IDH2 gene.

Use

The mutations in IDH1 or IDH2 are prevalent in various types of cancer, including but not limited to glioma, periosteal chondroma, chondrosarcoma, acute myeloid leukemia (AML) and cholangiocarcinoma. Targeted therapies are approved by the U.S. Food and Drug Administration (FDA) and/or recommended by National Comprehensive Cancer Network (NCCN) for the treatment of different malignancies with IDH1 or IDH2 mutations under certain circumstances, including AML, myelodysplastic syndromes, astrocytoma, oligodendroglioma, and chondrosarcoma.

Limitations

IDH1 and IDH2 Mutation Test can detect ≥5% of a mutant allele. IDH1 and IDH2 mutations other than those listed above will not be detected. This assay cannot differentiate among mutations at the same codon. Preparation of DNA from whole blood and bone marrow samples is dependent on the quality of the specimen provided. A negative (no mutation detected) result does not preclude the presence of such a mutation since results depend on, among other factors, mutant allele frequency, specimen integrity, absence of inhibitors and/or interfering polymorphisms, and availability of sufficient DNA for detection.

Specimen Type

Whole blood
Bone marrow
Extracted DNA

Container

Lavender/EDTA

Volume

Whole blood – 4 mL
Bone marrow – 4 mL
Extracted DNA – 200ng

Minimum Volume

Whole blood – <1 mL, if sufficient DNA is extracted from the blood
Bone marrow – <1 mL, if sufficient DNA is extracted from the bone marrow
Extracted DNA – 100ng

Shipping and Handling Instructions

Transport specimen at room temperature.

Causes for Rejection

Clotted specimen, improperly labelled specimen, broken specimen tube

Collect

Whole blood
Bone marrow
Extracted DNA
Test Information

CPT Codes

81120 - IDH1 Mutation Detection
81121 - IDH2 Mutation Detection

Synonyms

  • IDH1 [isocitrate dehydrogenase (NADP(+)) 1]
  • IDH2 [isocitrate dehydrogenase (NADP(+)) 2]
  • AML

Test Includes

IDH1 Mutation Detection – Identification of codon 132 mutations in IDH1 gene
IDH2 Mutation Detection – Identification of codon 140 and 172 mutations in IDH2 gene

Performing Laboratory / Facility

UCLA Molecular Diagnostics Laboratories (MDL)

Performing Section

Molecular Pathology

Availability

Monday through Friday, 0700-1700

Turnaround Time

2-5 business days from receipt of specimen in performing lab

Methodology

IDH1 and IDH2 Idylla Assay is a real- time PCR assay using a cartridge -based design for the detection of somatic mutations in IDH1 and IDH2 genes. The test detects mutations of R132C/H/G/S/L in codon 132 of the IDH1 gene. The test also detects mutations R140Q/L/G/W and R172K/M/G/S/W in codon 172 of the IDH2 gene.

Use

The mutations in IDH1 or IDH2 are prevalent in various types of cancer, including but not limited to glioma, periosteal chondroma, chondrosarcoma, acute myeloid leukemia (AML) and cholangiocarcinoma. Targeted therapies are approved by the U.S. Food and Drug Administration (FDA) and/or recommended by National Comprehensive Cancer Network (NCCN) for the treatment of different malignancies with IDH1 or IDH2 mutations under certain circumstances, including AML, myelodysplastic syndromes, astrocytoma, oligodendroglioma, and chondrosarcoma.

Limitations

IDH1 and IDH2 Mutation Test can detect ≥5% of a mutant allele. IDH1 and IDH2 mutations other than those listed above will not be detected. This assay cannot differentiate among mutations at the same codon. Preparation of DNA from whole blood and bone marrow samples is dependent on the quality of the specimen provided. A negative (no mutation detected) result does not preclude the presence of such a mutation since results depend on, among other factors, mutant allele frequency, specimen integrity, absence of inhibitors and/or interfering polymorphisms, and availability of sufficient DNA for detection.
Specimen Collection and Handling

Specimen Type

Whole blood
Bone marrow
Extracted DNA

Container

Lavender/EDTA

Volume

Whole blood – 4 mL
Bone marrow – 4 mL
Extracted DNA – 200ng

Minimum Volume

Whole blood – <1 mL, if sufficient DNA is extracted from the blood
Bone marrow – <1 mL, if sufficient DNA is extracted from the bone marrow
Extracted DNA – 100ng

Shipping and Handling Instructions

Transport specimen at room temperature.

Causes for Rejection

Clotted specimen, improperly labelled specimen, broken specimen tube

Collect

Whole blood
Bone marrow
Extracted DNA
Result Interpretation